Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC

NCT04143191 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

158

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib
PROCEDURE: Transarterial chemoembolization

Sponsor

Sun Yat-sen University